Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) Sees Large Decrease in Short Interest

Key Points

• Short interest plunged 30.6% to 17,252 shares as of March 31 (about 0.1% of float), with a days-to-cover ratio of just 0.4 days.
• Several institutions either initiated or increased stakes, including Context Capital (~$2.57M), Clear Street (~$2.15M), Wolverine (up 22.2% to 1,249,128 shares), Radcliffe (up 316.7% to 528,100 shares) and a new JPMorgan position (~$1.02M).
• Analyst consensus is "Sell" (Weiss Ratings reaffirmed a "sell (d-)"), while shares trade around $10.52, near their 52‑week high with 50‑day/200‑day SMAs of $10.48/$10.39.

Drugs Made In America Acquisition Corp. (NASDAQ:DMAA - Get Free Report) saw a large decline in short interest in the month of March. As of March 31st, there was short interest totaling 17,252 shares, a decline of 30.6% from the March 15th total of 24,866 shares. Approximately 0.1% of the company's shares are short sold. Based on an average daily trading volume, of 43,602 shares, the days-to-cover ratio is presently 0.4 days.

Hedge Funds Weigh In On Drugs Made In America Acquisition

Several institutional investors and hedge funds have recently modified their holdings of DMAA. Context Capital Management LLC bought a new stake in Drugs Made In America Acquisition in the 3rd quarter valued at approximately $2,568,000. Clear Street Group Inc. bought a new stake in Drugs Made In America Acquisition in the 3rd quarter valued at approximately $2,152,000. Wolverine Asset Management LLC lifted its stake in Drugs Made In America Acquisition by 22.2% in the 3rd quarter. Wolverine Asset Management LLC now owns 1,249,128 shares of the company's stock valued at $12,829,000 after acquiring an additional 227,222 shares in the last quarter. Radcliffe Capital Management L.P. lifted its stake in Drugs Made In America Acquisition by 316.7% in the 3rd quarter. Radcliffe Capital Management L.P. now owns 528,100 shares of the company's stock valued at $5,424,000 after acquiring an additional 401,378 shares in the last quarter. Finally, JPMorgan Chase & Co. bought a new stake in Drugs Made In America Acquisition in the 3rd quarter valued at approximately $1,024,000.

Drugs Made In America Acquisition Trading Down 0.0%

Shares of DMAA opened at $10.52 on Tuesday. The stock has a 50 day simple moving average of $10.48 and a 200 day simple moving average of $10.39. Drugs Made In America Acquisition has a 52-week low of $10.02 and a 52-week high of $10.52.

Analyst Ratings Changes

Separately, Weiss Ratings restated a "sell (d-)" rating on shares of Drugs Made In America Acquisition in a research report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Drugs Made In America Acquisition currently has a consensus rating of "Sell".

About Drugs Made In America Acquisition

Drugs Made In America Acquisition Corp NASDAQ: DMAA is a special purpose acquisition company incorporated in Delaware with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company's stated focus is on identifying and acquiring one or more operating businesses in the U.S. pharmaceutical sector, particularly those involved in the domestic manufacturing of approved drugs, active pharmaceutical ingredients or related contract development and manufacturing services.

Operating as a blank‐check vehicle, Drugs Made In America Acquisition holds its funds in a trust account pending the completion of an initial business combination.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.